| EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent N Mottet, J Bellmunt, M Bolla, E Briers, MG Cumberbatch, M De Santis, ... European urology 71 (4), 618-629, 2017 | 3662 | 2017 |
| EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent N Mottet, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology 79 (2), 243-262, 2021 | 2142 | 2021 |
| Mortality after surgery in Europe: a 7 day cohort study RM Pearse, RP Moreno, P Bauer, P Pelosi, P Metnitz, C Spies, B Vallet, ... The Lancet 380 (9847), 1059-1065, 2012 | 1426 | 2012 |
| EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer P Cornford, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology 79 (2), 263-282, 2021 | 820 | 2021 |
| The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review N Fossati, PPM Willemse, T Van den Broeck, RCN van den Bergh, ... European urology 72 (1), 84-109, 2017 | 488 | 2017 |
| Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review T Van den Broeck, RC Van Den Bergh, N Arfi, T Gross, L Moris, E Briers, ... European urology 75 (6), 967-987, 2019 | 414 | 2019 |
| What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the … PC Moldovan, T Van den Broeck, R Sylvester, L Marconi, J Bellmunt, ... European urology 72 (2), 250-266, 2017 | 388 | 2017 |
| EAU–ESTRO–ESUR–SIOG guidelines on prostate cancer N Mottet, J Bellmunt, E Briers, M Bolla, L Bourke, P Cornford, M De Santis, ... European Association of Urology, 2018 | 371 | 2018 |
| Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer F Abdollah, RJ Karnes, N Suardi, C Cozzarini, G Gandaglia, N Fossati, ... J Clin Oncol 32 (35), 3939-3947, 2014 | 346 | 2014 |
| Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review M Lardas, M Liew, RC van den Bergh, M De Santis, J Bellmunt, ... European urology 72 (6), 869-885, 2017 | 266 | 2017 |
| Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies A Necchi, D Raggi, A Gallina, R Madison, M Colecchia, R Luciano, ... European urology 77 (4), 439-446, 2020 | 264 | 2020 |
| A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance … G Gandaglia, G Ploussard, M Valerio, A Mattei, C Fiori, N Fossati, ... European urology 75 (3), 506-514, 2019 | 250 | 2019 |
| EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international … TBL Lam, S MacLennan, PPM Willemse, MD Mason, K Plass, R Shepherd, ... European urology 76 (6), 790-813, 2019 | 222 | 2019 |
| Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer G Gandaglia, N Fossati, E Zaffuto, M Bandini, P Dell’Oglio, CA Bravi, ... European urology 72 (4), 632-640, 2017 | 214 | 2017 |
| Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study N Fossati, QD Trinh, J Sammon, A Sood, A Larcher, M Sun, P Karakiewicz, ... European urology 67 (1), 3-6, 2015 | 179 | 2015 |
| Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations T Van den Broeck, RCN van den Bergh, E Briers, P Cornford, ... European urology focus 6 (2), 231-234, 2020 | 171 | 2020 |
| Long-term followup and deterioration rate of anterior substitution urethroplasty G Barbagli, SB Kulkarni, N Fossati, A Larcher, S Sansalone, G Guazzoni, ... The Journal of urology 192 (3), 808-813, 2014 | 161 | 2014 |
| Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review L Moris, MG Cumberbatch, T Van den Broeck, G Gandaglia, N Fossati, ... European urology 77 (5), 614-627, 2020 | 146 | 2020 |
| Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer A Necchi, D Raggi, A Gallina, JS Ross, E Farè, P Giannatempo, ... European urology 77 (6), 701-710, 2020 | 145 | 2020 |
| Active surveillance for low-risk prostate cancer: the European Association of Urology position in 2018 A Briganti, N Fossati, JWF Catto, P Cornford, F Montorsi, N Mottet, M Wirth, ... European urology 74 (3), 357-368, 2018 | 140 | 2018 |
Alberto BrigantiVita-Salute San Raffaele University, Milan, Italy在 hsr.it 的电子邮件经过验证
